MovDisordV3, Main, Merge, bibRecord, 007F57

Comparison of treatment of tardive dystonia and idiopathic cervical dystonia with botulinum toxin type A

Identifieur interne : 007F57 ( Main/Merge ); précédent : 007F56; suivant : 007F58

Comparison of treatment of tardive dystonia and idiopathic cervical dystonia with botulinum toxin type A

Auteurs : Brashear [États-Unis] ; Walter T. Ambrosius [États-Unis] ; George J. Eckert [États-Unis] ; Eric R. Siemers [États-Unis]

Source :

Movement Disorders [ 0885-3185 ] ; 1998-01.

RBID : ISTEX:2B62EE88EB98EEB1F2972AF810B69B71BCF88701

English descriptors

KwdEn :
- Adult, Aged, Antipsychotic Agents (adverse effects), Botulinum Toxins, Type A (therapeutic use), Botulinum toxin, Dystonia (chemically induced), Dystonia (drug therapy), Humans, Longitudinal Studies, Middle Aged, Neck Muscles (drug effects), Neuromuscular Agents (therapeutic use), Severity of Illness Index, Statistics, Nonparametric, Tardive dystonia, Torticollis, Torticollis (chemically induced), Torticollis (drug therapy), Treatment Outcome.
MESH :
- chemical , adverse effects : Antipsychotic Agents.
- chemical , therapeutic use : Botulinum Toxins, Type A, Neuromuscular Agents.
- chemically induced : Dystonia, Torticollis.
- drug effects : Neck Muscles.
- drug therapy : Dystonia, Torticollis.
- Adult, Aged, Humans, Longitudinal Studies, Middle Aged, Severity of Illness Index, Statistics, Nonparametric, Treatment Outcome.

Abstract

To compare clinical parameters of patients treated with botulinum toxin type A (BTX) for treatment of idiopathic cervical dystonia (ICD) and for tardive cervical dystonia (TCD), we studied 156 patients (149 with ICD and 7 with TCD) who were treated with serial injections of BTX over 5 years. We hypothesized that patients with TCD and ICD would demonstrate similar improvement in severity scores after treatment with BTX. The diagnosis, dates, dosages, and frequency of BTX injected and severity assessments were recorded into a computerized database. Nonparametric Wilcoxon rank sum and signed‐rank tests were used to assess statistical significance. The change in severity scores between the first treatment and last treatment in both groups was not statistically significant (p = 0.4859), indicating similar improvement. The difference in BTX doses was significant (p = 0.0045). ICD patients (n = 149) received an average of 219.8 ± 63.5 units and those with TCD (n = 7) were treated with an average dose of 287.4 ± 60.3 units. The average number of days between treatments for individuals with ICD was 142.9 ± 85.8, similar to that for persons with TCD (144.7 ± 64.5) (p = 0.6075). Our analysis provides preliminary evidence that the improvement from the administration of BTX for patients with ICD and TCD is similar.

Url:

https://api.istex.fr/document/2B62EE88EB98EEB1F2972AF810B69B71BCF88701/fulltext/pdf

DOI: 10.1002/mds.870130130

Links to Exploration step

ISTEX:2B62EE88EB98EEB1F2972AF810B69B71BCF88701

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Comparison of treatment of tardive dystonia and idiopathic cervical dystonia with botulinum toxin type A</title>
<author><name sortKey="Brashear" sort="Brashear" uniqKey="Brashear" last="Brashear">Brashear</name>
</author>
<author><name sortKey="Ambrosius, Walter T" sort="Ambrosius, Walter T" uniqKey="Ambrosius W" first="Walter T." last="Ambrosius">Walter T. Ambrosius</name>
</author>
<author><name sortKey="Eckert, George J" sort="Eckert, George J" uniqKey="Eckert G" first="George J." last="Eckert">George J. Eckert</name>
</author>
<author><name sortKey="Siemers, Eric R" sort="Siemers, Eric R" uniqKey="Siemers E" first="Eric R." last="Siemers">Eric R. Siemers</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:2B62EE88EB98EEB1F2972AF810B69B71BCF88701</idno>
<date when="1998" year="1998">1998</date>
<idno type="doi">10.1002/mds.870130130</idno>
<idno type="url">https://api.istex.fr/document/2B62EE88EB98EEB1F2972AF810B69B71BCF88701/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">002A73</idno>
<idno type="wicri:Area/Istex/Curation">002A73</idno>
<idno type="wicri:Area/Istex/Checkpoint">003780</idno>
<idno type="wicri:doubleKey">0885-3185:1998:Brashear:comparison:of:treatment</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:9452343</idno>
<idno type="wicri:Area/PubMed/Corpus">004500</idno>
<idno type="wicri:Area/PubMed/Curation">004500</idno>
<idno type="wicri:Area/PubMed/Checkpoint">004475</idno>
<idno type="wicri:Area/Ncbi/Merge">004E85</idno>
<idno type="wicri:Area/Ncbi/Curation">004E85</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">004E85</idno>
<idno type="wicri:doubleKey">0885-3185:1998:Brashear A:comparison:of:treatment</idno>
<idno type="wicri:Area/Main/Merge">007F57</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Comparison of treatment of tardive dystonia and idiopathic cervical dystonia with botulinum toxin type A</title>
<author><name sortKey="Brashear" sort="Brashear" uniqKey="Brashear" last="Brashear">Brashear</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology and Division of Biostatistics, Indiana University School of Medicine, Indianapolis, Indiana</wicri:regionArea>
<placeName><region type="state">Indiana</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ambrosius, Walter T" sort="Ambrosius, Walter T" uniqKey="Ambrosius W" first="Walter T." last="Ambrosius">Walter T. Ambrosius</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana</wicri:regionArea>
<placeName><region type="state">Indiana</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Eckert, George J" sort="Eckert, George J" uniqKey="Eckert G" first="George J." last="Eckert">George J. Eckert</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana</wicri:regionArea>
<placeName><region type="state">Indiana</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Siemers, Eric R" sort="Siemers, Eric R" uniqKey="Siemers E" first="Eric R." last="Siemers">Eric R. Siemers</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology and Division of Biostatistics, Indiana University School of Medicine, Indianapolis, Indiana</wicri:regionArea>
<placeName><region type="state">Indiana</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="1998-01">1998-01</date>
<biblScope unit="vol">13</biblScope>
<biblScope unit="issue">1</biblScope>
<biblScope unit="page" from="158">158</biblScope>
<biblScope unit="page" to="161">161</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">2B62EE88EB98EEB1F2972AF810B69B71BCF88701</idno>
<idno type="DOI">10.1002/mds.870130130</idno>
<idno type="ArticleID">MDS870130130</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Antipsychotic Agents (adverse effects)</term>
<term>Botulinum Toxins, Type A (therapeutic use)</term>
<term>Botulinum toxin</term>
<term>Dystonia (chemically induced)</term>
<term>Dystonia (drug therapy)</term>
<term>Humans</term>
<term>Longitudinal Studies</term>
<term>Middle Aged</term>
<term>Neck Muscles (drug effects)</term>
<term>Neuromuscular Agents (therapeutic use)</term>
<term>Severity of Illness Index</term>
<term>Statistics, Nonparametric</term>
<term>Tardive dystonia</term>
<term>Torticollis</term>
<term>Torticollis (chemically induced)</term>
<term>Torticollis (drug therapy)</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antipsychotic Agents</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Botulinum Toxins, Type A</term>
<term>Neuromuscular Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Dystonia</term>
<term>Torticollis</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Neck Muscles</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Dystonia</term>
<term>Torticollis</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Humans</term>
<term>Longitudinal Studies</term>
<term>Middle Aged</term>
<term>Severity of Illness Index</term>
<term>Statistics, Nonparametric</term>
<term>Treatment Outcome</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">To compare clinical parameters of patients treated with botulinum toxin type A (BTX) for treatment of idiopathic cervical dystonia (ICD) and for tardive cervical dystonia (TCD), we studied 156 patients (149 with ICD and 7 with TCD) who were treated with serial injections of BTX over 5 years. We hypothesized that patients with TCD and ICD would demonstrate similar improvement in severity scores after treatment with BTX. The diagnosis, dates, dosages, and frequency of BTX injected and severity assessments were recorded into a computerized database. Nonparametric Wilcoxon rank sum and signed‐rank tests were used to assess statistical significance. The change in severity scores between the first treatment and last treatment in both groups was not statistically significant (p = 0.4859), indicating similar improvement. The difference in BTX doses was significant (p = 0.0045). ICD patients (n = 149) received an average of 219.8 ± 63.5 units and those with TCD (n = 7) were treated with an average dose of 287.4 ± 60.3 units. The average number of days between treatments for individuals with ICD was 142.9 ± 85.8, similar to that for persons with TCD (144.7 ± 64.5) (p = 0.6075). Our analysis provides preliminary evidence that the improvement from the administration of BTX for patients with ICD and TCD is similar.</div>
</front>
</TEI>
<double doi="10.1002/mds.870130130"><ISTEX><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Comparison of treatment of tardive dystonia and idiopathic cervical dystonia with botulinum toxin type A</title>
<author><name sortKey="Brashear" sort="Brashear" uniqKey="Brashear" last="Brashear">Brashear</name>
</author>
<author><name sortKey="Ambrosius, Walter T" sort="Ambrosius, Walter T" uniqKey="Ambrosius W" first="Walter T." last="Ambrosius">Walter T. Ambrosius</name>
</author>
<author><name sortKey="Eckert, George J" sort="Eckert, George J" uniqKey="Eckert G" first="George J." last="Eckert">George J. Eckert</name>
</author>
<author><name sortKey="Siemers, Eric R" sort="Siemers, Eric R" uniqKey="Siemers E" first="Eric R." last="Siemers">Eric R. Siemers</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:2B62EE88EB98EEB1F2972AF810B69B71BCF88701</idno>
<date when="1998" year="1998">1998</date>
<idno type="doi">10.1002/mds.870130130</idno>
<idno type="url">https://api.istex.fr/document/2B62EE88EB98EEB1F2972AF810B69B71BCF88701/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">002A73</idno>
<idno type="wicri:Area/Istex/Curation">002A73</idno>
<idno type="wicri:Area/Istex/Checkpoint">003780</idno>
<idno type="wicri:doubleKey">0885-3185:1998:Brashear:comparison:of:treatment</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Comparison of treatment of tardive dystonia and idiopathic cervical dystonia with botulinum toxin type A</title>
<author><name sortKey="Brashear" sort="Brashear" uniqKey="Brashear" last="Brashear">Brashear</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology and Division of Biostatistics, Indiana University School of Medicine, Indianapolis, Indiana</wicri:regionArea>
<placeName><region type="state">Indiana</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ambrosius, Walter T" sort="Ambrosius, Walter T" uniqKey="Ambrosius W" first="Walter T." last="Ambrosius">Walter T. Ambrosius</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana</wicri:regionArea>
<placeName><region type="state">Indiana</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Eckert, George J" sort="Eckert, George J" uniqKey="Eckert G" first="George J." last="Eckert">George J. Eckert</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana</wicri:regionArea>
<placeName><region type="state">Indiana</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Siemers, Eric R" sort="Siemers, Eric R" uniqKey="Siemers E" first="Eric R." last="Siemers">Eric R. Siemers</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology and Division of Biostatistics, Indiana University School of Medicine, Indianapolis, Indiana</wicri:regionArea>
<placeName><region type="state">Indiana</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="1998-01">1998-01</date>
<biblScope unit="vol">13</biblScope>
<biblScope unit="issue">1</biblScope>
<biblScope unit="page" from="158">158</biblScope>
<biblScope unit="page" to="161">161</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">2B62EE88EB98EEB1F2972AF810B69B71BCF88701</idno>
<idno type="DOI">10.1002/mds.870130130</idno>
<idno type="ArticleID">MDS870130130</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Botulinum toxin</term>
<term>Tardive dystonia</term>
<term>Torticollis</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">To compare clinical parameters of patients treated with botulinum toxin type A (BTX) for treatment of idiopathic cervical dystonia (ICD) and for tardive cervical dystonia (TCD), we studied 156 patients (149 with ICD and 7 with TCD) who were treated with serial injections of BTX over 5 years. We hypothesized that patients with TCD and ICD would demonstrate similar improvement in severity scores after treatment with BTX. The diagnosis, dates, dosages, and frequency of BTX injected and severity assessments were recorded into a computerized database. Nonparametric Wilcoxon rank sum and signed‐rank tests were used to assess statistical significance. The change in severity scores between the first treatment and last treatment in both groups was not statistically significant (p = 0.4859), indicating similar improvement. The difference in BTX doses was significant (p = 0.0045). ICD patients (n = 149) received an average of 219.8 ± 63.5 units and those with TCD (n = 7) were treated with an average dose of 287.4 ± 60.3 units. The average number of days between treatments for individuals with ICD was 142.9 ± 85.8, similar to that for persons with TCD (144.7 ± 64.5) (p = 0.6075). Our analysis provides preliminary evidence that the improvement from the administration of BTX for patients with ICD and TCD is similar.</div>
</front>
</TEI>
</ISTEX>
<PubMed><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Comparison of treatment of tardive dystonia and idiopathic cervical dystonia with botulinum toxin type A.</title>
<author><name sortKey="Brashear, A" sort="Brashear, A" uniqKey="Brashear A" first="A" last="Brashear">A. Brashear</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, Indiana University School of Medicine, Indianapolis, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, Indiana University School of Medicine, Indianapolis</wicri:regionArea>
<wicri:noRegion>Indianapolis</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Ambrosius, W T" sort="Ambrosius, W T" uniqKey="Ambrosius W" first="W T" last="Ambrosius">W T Ambrosius</name>
</author>
<author><name sortKey="Eckert, G J" sort="Eckert, G J" uniqKey="Eckert G" first="G J" last="Eckert">G J Eckert</name>
</author>
<author><name sortKey="Siemers, E R" sort="Siemers, E R" uniqKey="Siemers E" first="E R" last="Siemers">E R Siemers</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="1998">1998</date>
<idno type="RBID">pubmed:9452343</idno>
<idno type="pmid">9452343</idno>
<idno type="doi">10.1002/mds.870130130</idno>
<idno type="wicri:Area/PubMed/Corpus">004500</idno>
<idno type="wicri:Area/PubMed/Curation">004500</idno>
<idno type="wicri:Area/PubMed/Checkpoint">004475</idno>
<idno type="wicri:Area/Ncbi/Merge">004E85</idno>
<idno type="wicri:Area/Ncbi/Curation">004E85</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">004E85</idno>
<idno type="wicri:doubleKey">0885-3185:1998:Brashear A:comparison:of:treatment</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Comparison of treatment of tardive dystonia and idiopathic cervical dystonia with botulinum toxin type A.</title>
<author><name sortKey="Brashear, A" sort="Brashear, A" uniqKey="Brashear A" first="A" last="Brashear">A. Brashear</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, Indiana University School of Medicine, Indianapolis, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, Indiana University School of Medicine, Indianapolis</wicri:regionArea>
<wicri:noRegion>Indianapolis</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Ambrosius, W T" sort="Ambrosius, W T" uniqKey="Ambrosius W" first="W T" last="Ambrosius">W T Ambrosius</name>
</author>
<author><name sortKey="Eckert, G J" sort="Eckert, G J" uniqKey="Eckert G" first="G J" last="Eckert">G J Eckert</name>
</author>
<author><name sortKey="Siemers, E R" sort="Siemers, E R" uniqKey="Siemers E" first="E R" last="Siemers">E R Siemers</name>
</author>
</analytic>
<series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="1998" type="published">1998</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Antipsychotic Agents (adverse effects)</term>
<term>Botulinum Toxins, Type A (therapeutic use)</term>
<term>Dystonia (chemically induced)</term>
<term>Dystonia (drug therapy)</term>
<term>Humans</term>
<term>Longitudinal Studies</term>
<term>Middle Aged</term>
<term>Neck Muscles (drug effects)</term>
<term>Neuromuscular Agents (therapeutic use)</term>
<term>Severity of Illness Index</term>
<term>Statistics, Nonparametric</term>
<term>Torticollis (chemically induced)</term>
<term>Torticollis (drug therapy)</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antipsychotic Agents</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Botulinum Toxins, Type A</term>
<term>Neuromuscular Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Dystonia</term>
<term>Torticollis</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Neck Muscles</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Dystonia</term>
<term>Torticollis</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Humans</term>
<term>Longitudinal Studies</term>
<term>Middle Aged</term>
<term>Severity of Illness Index</term>
<term>Statistics, Nonparametric</term>
<term>Treatment Outcome</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">To compare clinical parameters of patients treated with botulinum toxin type A (BTX) for treatment of idiopathic cervical dystonia (ICD) and for tardive cervical dystonia (TCD), we studied 156 patients (149 with ICD and 7 with TCD) who were treated with serial injections of BTX over 5 years. We hypothesized that patients with TCD and ICD would demonstrate similar improvement in severity scores after treatment with BTX. The diagnosis, dates, dosages, and frequency of BTX injected and severity assessments were recorded into a computerized database. Nonparametric Wilcoxon rank sum and signed-rank tests were used to assess statistical significance. The change in severity scores between the first treatment and last treatment in both groups was not statistically significant (p = 0.4859), indicating similar improvement. The difference in BTX doses was significant (p = 0.0045). ICD patients (n = 149) received an average of 219.8 +/- 63.5 units and those with TCD (n = 7) were treated with an average dose of 287.4 +/- 60.3 units. The average number of days between treatments for individuals with ICD was 142.9 +/- 85.8, similar to that for persons with TCD (144.7 +/- 64.5) (p = 0.6075). Our analysis provides preliminary evidence that the improvement from the administration of BTX for patients with ICD and TCD is similar.</div>
</front>
</TEI>
</PubMed>
</double>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Merge

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 007F57 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 007F57 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Merge
   |type=    RBID
   |clé=     ISTEX:2B62EE88EB98EEB1F2972AF810B69B71BCF88701
   |texte=   Comparison of treatment of tardive dystonia and idiopathic cervical dystonia with botulinum toxin type A
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

Movement Disorders (revue)

Comparison of treatment of tardive dystonia and idiopathic cervical dystonia with botulinum toxin type A

Comparison of treatment of tardive dystonia and idiopathic cervical dystonia with botulinum toxin type A

Source :

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.